Genesis Bioventures Announces Name Change to Abviva, Inc.

Genesis Bioventures, Inc. (GBI) (OTCBB:GBIW) today announced that it has completed its planned name change of the corporation to Abviva, Inc. Genesis Bioventures changed its corporate name to Abviva, Inc. to emphasize its mission to commercialize the Mammastatin Serum Assay ("MSA”) and to pursue development of the mammastatin protein as a possible first line therapy against breast cancer. The name change was approved by the shareholders at the 2007 Annual Shareholders Meeting held on September 14, 2007 as part of the Company’s completion of its reorganization and restructuring plan. "We determined that the Company requires a name that represents its mission and commitment to the mammastatin technology for breast cancer diagnostics and therapeutics,” said Douglas C. Lane, President and CEO. Abviva is a name inspired from a Latin phrase meaning ‘From Life’. Mammastatin is normally present in healthy women and therefore comes from life. This technology is used to develop and offer innovative diagnostic and therapeutic products ‘For Life’, beginning with the Mammastatin Serum Assay.” The Company will continue to be traded under the ticker symbol GBIW on the NASD OTCBB market. The Company has applied for a new ticker symbol representative of its new name. Abviva will announce the new ticker symbol when it receives notice from the regulatory agencies. The Company’s new website is under construction and will be available at www.abviva.com. About Abviva (formerly known as Genesis Bioventures, Inc.) Abviva, Inc. is a biomedical company focused on the commercialization of its owned and licensed assets for breast cancer diagnostics and for breast cancer therapeutic development. Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.